Carcinoma Ex Benign Pleomorphic Adenoma of the Parotid Gland

Nouraei, S.A.R.; Hope, Kirsten; Kelly, Charles; McLean, N.R.; Soames, J.V.

doi:10.1097/01.prs.0000181654.68120.0f

Cited by 78 publications

(107 citation statements)

References 25 publications

Supporting

Mentioning

101

Contrasting

Unclassified

Order By: Relevance

“…Nouraei et al [2] reported the presence of a parotid mass in 96% of the 25 patients examined, whereas Olsen and Lewis noted a parotid mass in 86% of the 66 patients examined [2,7].…”

Section: Clinical Featuresmentioning

confidence: 99%

“…Nouraei et al [2] and Zbären et al [6] observed that 25% of their 28 patients and 21% of their 24 patients, respectively, had a previously treated pleomorphic adenoma.…”

Section: Clinical Featuresmentioning

confidence: 99%

“…Also, the clinical presentation may mimic a multiple facial nerve schwannoma [14]. In some instances, patients with Ca ex PA were reported to present with skin ulceration, tumour fungation, skin fixation, palpable lymphadenopathy and dysphagia [2,7]. In addition, they may have swollen jaw (due to bone invasion), dental pain, and sudden loss of vitality [15].…”

Section: Clinical Featuresmentioning

confidence: 99%

“…Ca ex PA has been named as carcinoma ex mixed tumour, carcinoma ex adenoma, and carcinoma ex benign pleomorphic adenoma [1][2][3]. The current definition of Ca ex PA became widely accepted in the second half of the twentieth century.…”

Section: Introductionmentioning

confidence: 99%

“…Carcinoma ex pleomorphic adenoma (Ca ex PA) is defined as a carcinoma arising from a primary (de novo) or recurrent benign pleomorphic adenoma (PA) [1,2]. Ca ex PA has been named as carcinoma ex mixed tumour, carcinoma ex adenoma, and carcinoma ex benign pleomorphic adenoma [1][2][3].…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Carcinoma ex Pleomorphic Adenoma: A Comprehensive Review of Clinical, Pathological and Molecular Data

Antony

Gopalan

Smith

et al. 2011

Head and Neck Pathol

214

243

View full text Add to dashboard Cite

Carcinoma ex pleomorphic adenoma (Ca ex PA) is a carcinoma arising from a primary or recurrent benign pleomorphic adenoma. It often poses a diagnostic challenge to clinicians and pathologists. This study intends to review the literature and highlight the current clinical and molecular perspectives about this entity. The most common clinical presentation of CA ex PA is of a firm mass in the parotid gland. The proportion of adenoma and carcinoma components determines the macroscopic features of this neoplasm. The entity is difficult to diagnose pre-operatively. Pathologic assessment is the gold standard for making the diagnosis. Treatment for Ca ex PA often involves an ablative surgical procedure which may be followed by radiotherapy. Overall, patients with Ca ex PA have a poor prognosis. Accurate diagnosis and aggressive surgical management of patients presenting with Ca ex PA can increase their survival rates. Molecular studies have revealed that the development of Ca ex PA follows a multistep model of carcinogenesis, with the progressive loss of heterozygosity at chromosomal arms 8q, then 12q and finally 17p. There are specific candidate genes in these regions that are associated with particular stages in the progression of Ca ex PA. In addition, many genes which regulate tumour suppression, cell cycle control, growth factors and cell-cell adhesion play a role in the development and progression of Ca ex PA. It is hopeful that these molecular data can give clues for the diagnosis and management of the disease.

show abstract

“…Nouraei et al [2] reported the presence of a parotid mass in 96% of the 25 patients examined, whereas Olsen and Lewis noted a parotid mass in 86% of the 66 patients examined [2,7].…”

Section: Clinical Featuresmentioning

confidence: 99%

“…Nouraei et al [2] and Zbären et al [6] observed that 25% of their 28 patients and 21% of their 24 patients, respectively, had a previously treated pleomorphic adenoma.…”

Section: Clinical Featuresmentioning

confidence: 99%